Vancomycin Area Under the Curve and Acute Kidney Injury: A Meta-analysis.
AUC
nephrotoxicity
vancomycin
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
13 11 2019
13 11 2019
Historique:
received:
02
10
2018
accepted:
15
01
2019
pubmed:
5
2
2019
medline:
15
9
2020
entrez:
5
2
2019
Statut:
ppublish
Résumé
This study analyzed the relationship between vancomycin area under the concentration-time curve (AUC) and acute kidney injury (AKI) reported across recent studies. A systematic review of PubMed, Medline, Scopus, and compiled references was conducted. We included randomized cohort and case-control studies that reported vancomycin AUCs and risk of AKI (from 1990 to 2018). The primary outcome was AKI, defined as an increase in serum creatinine of ≥0.5 mg/L or a 50% increase from baseline on ≥2 consecutive measurements. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Primary analyses compared the impact of AUC cutpoint (greater than ~650 mg × hour/L) and AKI. Additional analysis compared AUC vs trough-guided monitoring on AKI incidence. Eight observational studies met inclusion/exclusion criteria with data for 2491 patients. Five studies reported first-24-hour AUCs (AUC0-24) and AKI, 2 studies reported 24- to 48-hour AUCs (AUC24-48) and AKI, and 2 studies reported AKI associated with AUC- vs trough-guided monitoring. AUC less than approximately 650 mg × hour/L was associated with decreased AKI for AUC0-24 (OR, 0.36 [95% CI, .23-.56]) as well as AUC24-48 (OR, 0.45 [95% CI, .27-.75]). AKI associated with the AUC monitoring strategy was significantly lower than trough-guided monitoring (OR, 0.68 [95% CI, .46-.99]). AUCs measured in the first or second 24 hours and lower than approximately 650 mg × hour/L may result in a decreased risk of AKI. Vancomycin AUC monitoring strategy may result in less vancomycin-associated AKI. Additional investigations are warranted.
Sections du résumé
BACKGROUND
This study analyzed the relationship between vancomycin area under the concentration-time curve (AUC) and acute kidney injury (AKI) reported across recent studies.
METHODS
A systematic review of PubMed, Medline, Scopus, and compiled references was conducted. We included randomized cohort and case-control studies that reported vancomycin AUCs and risk of AKI (from 1990 to 2018). The primary outcome was AKI, defined as an increase in serum creatinine of ≥0.5 mg/L or a 50% increase from baseline on ≥2 consecutive measurements. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Primary analyses compared the impact of AUC cutpoint (greater than ~650 mg × hour/L) and AKI. Additional analysis compared AUC vs trough-guided monitoring on AKI incidence.
RESULTS
Eight observational studies met inclusion/exclusion criteria with data for 2491 patients. Five studies reported first-24-hour AUCs (AUC0-24) and AKI, 2 studies reported 24- to 48-hour AUCs (AUC24-48) and AKI, and 2 studies reported AKI associated with AUC- vs trough-guided monitoring. AUC less than approximately 650 mg × hour/L was associated with decreased AKI for AUC0-24 (OR, 0.36 [95% CI, .23-.56]) as well as AUC24-48 (OR, 0.45 [95% CI, .27-.75]). AKI associated with the AUC monitoring strategy was significantly lower than trough-guided monitoring (OR, 0.68 [95% CI, .46-.99]).
CONCLUSIONS
AUCs measured in the first or second 24 hours and lower than approximately 650 mg × hour/L may result in a decreased risk of AKI. Vancomycin AUC monitoring strategy may result in less vancomycin-associated AKI. Additional investigations are warranted.
Identifiants
pubmed: 30715208
pii: 5305676
doi: 10.1093/cid/ciz051
pmc: PMC6853683
doi:
Substances chimiques
Anti-Bacterial Agents
0
Vancomycin
6Q205EH1VU
Types de publication
Journal Article
Meta-Analysis
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1881-1887Subventions
Organisme : NIAID NIH HHS
ID : R15 AI105742
Pays : United States
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
PLoS Med. 2012;9(10):e1001333
pubmed: 23222917
Clin Infect Dis. 2009 Aug 1;49(3):325-7
pubmed: 19569969
Ann Pharmacother. 2017 Mar;51(3):185-193
pubmed: 27838680
Chemotherapy. 2012;58(4):308-12
pubmed: 23147106
Antimicrob Agents Chemother. 2017 Apr 24;61(5):
pubmed: 28242672
Clin Infect Dis. 2012 Mar;54(6):755-71
pubmed: 22302374
Infect Control Hosp Epidemiol. 2016 Jan;37(1):70-9
pubmed: 26456803
Int J Antimicrob Agents. 2018 Feb;51(2):239-243
pubmed: 28803934
Antimicrob Agents Chemother. 2017 Dec 21;62(1):
pubmed: 29084753
Clin Infect Dis. 2012 Mar 1;54(5):621-9
pubmed: 22247123
Int J Antimicrob Agents. 2018 Dec;52(6):805-810
pubmed: 30176357
Clin Ther. 2012 Jan;34(1):149-57
pubmed: 22284995
Antimicrob Agents Chemother. 2017 Nov 22;61(12):
pubmed: 28923869
Int J Antimicrob Agents. 2015 Sep;46(3):249-53
pubmed: 26141230
Clin Pharmacol Ther. 2017 Sep;102(3):459-469
pubmed: 28474732
Crit Care Med. 2014 Dec;42(12):2527-36
pubmed: 25083977
J Antimicrob Chemother. 2009 May;63(5):849-61
pubmed: 19282331
Clin Infect Dis. 2011 Feb 1;52(3):285-92
pubmed: 21217178
Antimicrob Agents Chemother. 2016 Sep 23;60(10):5742-51
pubmed: 27431226
Pharmacotherapy. 2015 Oct;35(10):889-98
pubmed: 26497475
Clin Infect Dis. 2009 Aug 15;49(4):507-14
pubmed: 19586413
Nephron Clin Pract. 2012;120(4):c179-84
pubmed: 22890468
Antimicrob Agents Chemother. 2018 Feb 23;62(3):
pubmed: 29263057
Clin Infect Dis. 2011 Apr 15;52(8):969-74
pubmed: 21460308
BMC Infect Dis. 2014 Apr 04;14:183
pubmed: 24708675
Eur J Clin Pharmacol. 2012 Sep;68(9):1243-55
pubmed: 22411630
Antimicrob Agents Chemother. 2018 Jan 25;62(2):
pubmed: 29203493
Antimicrob Agents Chemother. 2008 Apr;52(4):1330-6
pubmed: 18227177
Ann Pharmacother. 2012 Nov;46(11):1477-83
pubmed: 23073306
Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S5-12
pubmed: 16323120
Antimicrob Agents Chemother. 2014;58(1):309-16
pubmed: 24165176
J Antimicrob Chemother. 2012 Jan;67(1):17-24
pubmed: 22028203
BMC Pharmacol Toxicol. 2013 Feb 13;14:12
pubmed: 23402420
Clin Infect Dis. 2020 Apr 10;70(8):1536-1545
pubmed: 31157370
Antimicrob Agents Chemother. 2017 Oct 24;61(11):
pubmed: 28807910